|
|
Diabetes R & D Pipeline: GLP-1 Agonists, Analogs and Allosteric ModulatorsPublished by: BioPolaris Published: Oct. 1, 2009 - 64 Pages Table of Contents
AbstractThe worldwide market for anti-diabetic therapeutic products is large and highly competitive. The global antidiabetic market is estimated to be over $24 billion in 2008. The largest players in this market are AstraZeneca plc (UK), Bristol-Myers Squibb Co. (USA), Eli Lilly & Co. (USA), GlaxoSmithKline plc (UK), Merck & Co. (USA), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Pfizer, Inc. (USA), Sanofi-Aventis SA (France) and Takeda Pharmaceutical Co., Ltd. (Japan), all of them selling or developing new therapeutic products for the treatment of diabetes.GLP-1 agonist, analogs and positive allosteric modulators are a relatively new class of anti-diabetic compounds and the largest of diabetes R & D therapeutic pipelines. The first GLP-1 agonist approved by the US Food and Drug Administration (FDA) was exenatide (Byetta®), approved in May 2005. In late 2006, Byetta® was approved in the EU and, by the end of 2008, was commercially launched in 49 countries worldwide. The first approved GLP-1 analog was liraglutide (Victoza®, NN2211), approved in the EU in July 2009. For the fullyear of 2008, worldwide Byetta sales increased 16% to $751.4 million. The USA Byetta sales for 2008 grew 7% to $678.5 million. Byetta sales outside the USA were $72.9 million. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||